Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target

Compare

1,157 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GPCR Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Structure

Therapeutics, Inc. Sponsored ADR

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GPCR Stock 12 Month Forecast

Average Price Target

$101.55

▲(60.55% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Structure Therapeutics, Inc. Sponsored ADR in the last 3 months. The average price target is $101.55 with a high forecast of $125.00 and a low forecast of $65.00. The average price target represents a 60.55% change from the last price of $63.25.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","42":"$42","70":"$70","98":"$98","126":"$126"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$101.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,42,70,98,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,41.526153846153846,48.48230769230769,55.43846153846154,62.39461538461539,69.35076923076923,76.30692307692308,83.26307692307694,90.21923076923078,97.17538461538462,104.13153846153847,111.08769230769232,118.04384615384618,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,39.722307692307695,44.87461538461538,50.026923076923076,55.17923076923077,60.33153846153846,65.48384615384614,70.63615384615383,75.78846153846153,80.94076923076923,86.09307692307692,91.24538461538461,96.3976923076923,{"y":101.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.57,36.91076923076923,39.25153846153846,41.59230769230769,43.933076923076925,46.27384615384615,48.614615384615384,50.95538461538462,53.29615384615384,55.636923076923075,57.97769230769231,60.318461538461534,62.65923076923077,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$125.00

Average Price Target$101.55

Lowest Price Target$65.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ananda Ghosh

H.C. Wainwright

$60→$90

Buy

42.29%

Upside

Reiterated

12/19/25

Structure Therapeutics price target raised to $90 from $60 at H.C. WainwrightStructure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

Jonathan Wolleben

Citizens JMP

$87→$120

Buy

89.72%

Upside

Reiterated

12/12/25

Structure Therapeutics price target raised to $120 from $87 at CitizensStructure Therapeutics price target raised to $120 from $87 at Citizens

Terence Flynn

Morgan Stanley

$120→$125

Buy

97.63%

Upside

Reiterated

12/12/25

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Morgan Stanley

Roger Song

Jefferies

$79→$125

Buy

97.63%

Upside

Reiterated

12/11/25

Jefferies Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Samantha Semenkow

Citi

$60→$100

Buy

58.10%

Upside

Reiterated

12/09/25

Structure Therapeutics price target raised to $100 from $60 at CitiStructure Therapeutics price target raised to $100 from $60 at Citi

Kaveri Pohlman

Clear Street

$61→$99

Buy

56.52%

Upside

Reiterated

12/09/25

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Clear Street

Annabel Samimy

Stifel Nicolaus

$50→$90

Buy

42.29%

Upside

Reiterated

12/08/25

Structure Therapeutics price target raised to $90 from $50 at StifelStructure Therapeutics price target raised to $90 from $50 at Stifel

Patrick Dolezal

LifeSci Capital

$72→$110

Buy

73.91%

Upside

Reiterated

12/08/25

Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment

Andy Hsieh

William Blair

Buy

―

Reiterated

12/08/25

Analysts' Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Sionna Therapeutics, Inc. (SION)

Hardik Parikh

J.P. Morgan

Buy

―

Reiterated

12/08/25

Promising Outlook for Structure Therapeutics' Aleniglipron: Buy Rating Affirmed Amid Strong Phase 2b Results and Market Potential

Evan Seigerman

BMO Capital

$100

Buy

58.10%

Upside

Reiterated

11/20/25

Buy Rating on Structure Therapeutics, Inc. Driven by Aleniglipron's Potential in the Obesity Market

Prakhar Agrawal

Cantor Fitzgerald

$65

Buy

2.77%

Upside

Reiterated

11/13/25

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Cantor Fitzgerald

Yasmeen Rahimi

Piper Sandler

$93

Buy

47.04%

Upside

Reiterated

10/28/25

Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

David Risinger

Leerink Partners

$60→$44

Buy

-30.43%

Downside

Reiterated

08/07/25

Structure Therapeutics price target lowered to $44 from $60 at LeerinkStructure Therapeutics price target lowered to $44 from $60 at Leerink

Seamus Fernandez

Guggenheim

$92→$90

Buy

42.29%

Upside

Reiterated

08/06/25

Structure Therapeutics price target lowered to $90 from $92 at GuggenheimStructure Therapeutics price target lowered to $90 from $92 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ananda Ghosh

H.C. Wainwright

$60→$90

Buy

42.29%

Upside

Reiterated

12/19/25

Structure Therapeutics price target raised to $90 from $60 at H.C. WainwrightStructure Therapeutics price target raised to $90 from $60 at H.C. Wainwright

Jonathan Wolleben

Citizens JMP

$87→$120

Buy

89.72%

Upside

Reiterated

12/12/25

Structure Therapeutics price target raised to $120 from $87 at CitizensStructure Therapeutics price target raised to $120 from $87 at Citizens

Terence Flynn

Morgan Stanley

$120→$125

Buy

97.63%

Upside

Reiterated

12/12/25

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Morgan Stanley

Roger Song

Jefferies

$79→$125

Buy

97.63%

Upside

Reiterated

12/11/25

Jefferies Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Samantha Semenkow

Citi

$60→$100

Buy

58.10%

Upside

Reiterated

12/09/25

Structure Therapeutics price target raised to $100 from $60 at CitiStructure Therapeutics price target raised to $100 from $60 at Citi

Kaveri Pohlman

Clear Street

$61→$99

Buy

56.52%

Upside

Reiterated

12/09/25

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Clear Street

Annabel Samimy

Stifel Nicolaus

$50→$90

Buy

42.29%

Upside

Reiterated

12/08/25

Structure Therapeutics price target raised to $90 from $50 at StifelStructure Therapeutics price target raised to $90 from $50 at Stifel

Patrick Dolezal

LifeSci Capital

$72→$110

Buy

73.91%

Upside

Reiterated

12/08/25

Positive Outlook for Structure Therapeutics: Aleniglipron Shows Promising Results in Obesity Treatment

Andy Hsieh

William Blair

Buy

―

Reiterated

12/08/25

Analysts' Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Sionna Therapeutics, Inc. (SION)

Hardik Parikh

J.P. Morgan

Buy

―

Reiterated

12/08/25

Promising Outlook for Structure Therapeutics' Aleniglipron: Buy Rating Affirmed Amid Strong Phase 2b Results and Market Potential

Evan Seigerman

BMO Capital

$100

Buy

58.10%

Upside

Reiterated

11/20/25

Buy Rating on Structure Therapeutics, Inc. Driven by Aleniglipron's Potential in the Obesity Market

Prakhar Agrawal

Cantor Fitzgerald

$65

Buy

2.77%

Upside

Reiterated

11/13/25

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Cantor Fitzgerald

Yasmeen Rahimi

Piper Sandler

$93

Buy

47.04%

Upside

Reiterated

10/28/25

Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

David Risinger

Leerink Partners

$60→$44

Buy

-30.43%

Downside

Reiterated

08/07/25

Structure Therapeutics price target lowered to $44 from $60 at LeerinkStructure Therapeutics price target lowered to $44 from $60 at Leerink

Seamus Fernandez

Guggenheim

$92→$90

Buy

42.29%

Upside

Reiterated

08/06/25

Structure Therapeutics price target lowered to $90 from $92 at GuggenheimStructure Therapeutics price target lowered to $90 from $92 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+8.72%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +8.72% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+14.06%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +14.06% per trade.

1 Year

Ananda GhoshH.C. Wainwright

Success Rate

9/10 ratings generated profit

Average Return

+161.39%

reiterated a buy rating 5 days ago

Copying Ananda Ghosh's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +161.39% per trade.

2 Years

xxx

Success Rate

9/10 ratings generated profit

Average Return

+161.39%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +161.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GPCR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GPCR has received 26 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GPCR average Analyst price target in the past 3 months is 101.55.

Each month's total comprises the sum of three months' worth of ratings.

GPCR Financial Forecast

GPCR Earnings Forecast

Next quarter’s earnings estimate for GPCR is -$0.38 with a range of -$0.48 to -$0.29. The previous quarter’s EPS was -$0.37. GPCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GPCR has Performed in-line its overall industry.

No data currently available

GPCR Sales Forecast

Next quarter’s sales forecast for GPCR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. GPCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GPCR has Performed in-line its overall industry.

GPCR Stock Forecast FAQ

What is GPCR’s average 12-month price target, according to analysts?

Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is 101.55.

What is GPCR’s upside potential, based on the analysts’ average price target?

Structure Therapeutics, Inc. Sponsored ADR has 60.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GPCR a Buy, Sell or Hold?

Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Structure Therapeutics, Inc. Sponsored ADR’s price target?

The average price target for Structure Therapeutics, Inc. Sponsored ADR is 101.55. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $65.00. The average price target represents 60.55% Increase from the current price of $63.25.

What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?

Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of GPCR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target

GPCR Analyst Ratings

GPCR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR

GPCR Analyst Recommendation Trends

GPCR Financial Forecast

GPCR Earnings Forecast

GPCR Sales Forecast

GPCR Stock Forecast FAQ

Detailed List of Analyst Forecasts